The Cooper Companies, Inc. $COO Stock: Robeco Institutional Asset Management B.V. Grows Holdings

Robeco Institutional Asset Management B.V. raised its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 834.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 112,677 shares of the medical device company’s stock after purchasing an additional 100,621 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.06% of Cooper Companies worth $6,370,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of COO. BlackRock Inc. acquired a new stake in shares of Cooper Companies in the second quarter valued at $1,077,762,000. Generation Investment Management LLP bought a new position in Cooper Companies during the second quarter valued at about $356,304,000. Jupiter Topco LLC acquired a new position in Cooper Companies during the second quarter worth about $305,074,000. JANA Partners Management LP grew its holdings in Cooper Companies by 0.5% during the second quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company’s stock worth $256,900,000 after acquiring an additional 17,322 shares during the period. Finally, Wellington Management Group LLP raised its position in Cooper Companies by 3.1% in the second quarter. Wellington Management Group LLP now owns 3,468,951 shares of the medical device company’s stock worth $248,758,000 after acquiring an additional 103,044 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Cooper Companies

In other news, Director Walter Rosebrough, Jr. acquired 3,000 shares of Cooper Companies stock in a transaction on Monday, September 14th. The stock was bought at an average cost of $54.29 per share, with a total value of $162,870.00. Following the completion of the purchase, the director owned 20,000 shares of the company’s stock, valued at $1,085,800. This represents a 17.65% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lawrence Kurzius bought 10,000 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was purchased at an average price of $54.93 per share, with a total value of $549,300.00. Following the completion of the acquisition, the director owned 31,099 shares of the company’s stock, valued at approximately $1,708,268.07. This trade represents a 47.40% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders bought 34,701 shares of company stock valued at $1,880,039. 2.08% of the stock is currently owned by corporate insiders.

Cooper Companies Stock Down 0.7%

Shares of Cooper Companies stock opened at $61.21 on Friday. The stock’s fifty day moving average is $61.79 and its 200-day moving average is $65.77. The firm has a market capitalization of $11.64 billion, a PE ratio of 20.89, a price-to-earnings-growth ratio of 2.49 and a beta of 0.83. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23. The Cooper Companies, Inc. has a 12-month low of $51.01 and a 12-month high of $89.83.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.12 by $0.03. The business had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. Cooper Companies’s revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities analysts anticipate that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies declared that its board has authorized a stock repurchase program on Wednesday, September 9th that permits the company to buy back $3.00 billion in shares. This buyback authorization permits the medical device company to reacquire up to 22.7% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Piper Sandler reissued a “neutral” rating on shares of Cooper Companies in a report on Thursday, October 15th. Needham & Company LLC lowered their price objective on shares of Cooper Companies from $86.00 to $73.00 and set a “buy” rating on the stock in a research note on Thursday, September 10th. Stifel Nicolaus set a $70.00 target price on shares of Cooper Companies and gave the stock a “buy” rating in a report on Thursday, September 10th. Zacks Research lowered shares of Cooper Companies from a “hold” rating to a “strong sell” rating in a research note on Friday, September 11th. Finally, UBS Group cut their target price on shares of Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a research note on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $68.60.

Cooper Companies Company Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.